Mounjaro vs Saxenda: What You Should Know

As prescription weight-loss medications have evolved, patients in New Zealand are now faced with more options than ever before. Two treatments that are often compared are Mounjaro (tirzepatide) and Saxenda (liraglutide). While both are injectable medications designed to support weight loss, they differ in how they work, how often they’re taken, and how patients may experience results.

Understanding these differences is important for anyone considering medical weight-loss support or reviewing options with a GP.

This article explains how Mounjaro and Saxenda compare in terms of mechanism of action, dosing, side effects, effectiveness, and availability in New Zealand.

How Mounjaro and Saxenda work

Saxenda contains liraglutide, a medication that mimics the GLP-1 hormone. GLP-1 helps regulate appetite by slowing stomach emptying and increasing feelings of fullness. By acting on this pathway, Saxenda can reduce hunger and calorie intake over time.

Mounjaro contains tirzepatide, which works differently. Instead of targeting only GLP-1, tirzepatide activates two hormone receptors: GLP-1 and GIP. These hormones work together to influence appetite, satiety, and blood sugar regulation.

This dual mechanism is one reason Mounjaro has attracted attention internationally, as it may provide stronger appetite suppression and metabolic effects for some patients. However, a stronger mechanism does not automatically mean it is the right choice for everyone.

Dosing frequency and convenience

One of the most noticeable differences between the two medications is how often they are taken.

Saxenda is injected once daily. This requires consistent daily administration, which some patients find manageable, while others find it difficult to maintain long term.

Mounjaro is injected once weekly. Weekly dosing can be more convenient and easier to fit into daily life, particularly for patients who struggle with adherence.

For many people, convenience plays a major role in treatment success. A medication that fits more naturally into a routine is more likely to be taken consistently.

Side effects and tolerability

Both Saxenda and Mounjaro share similar side-effect profiles because they act on appetite and digestion.

Common side effects include:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Reduced appetite

• Bloating or reflux

  
  

These effects are most common during dose increases and often improve as the body adjusts. Gradual dose escalation is essential for minimising discomfort with both medications.

Some patients tolerate one medication better than the other. This variability is one of the reasons GP supervision is important — side effects are not always predictable.

Severe or persistent symptoms should always be reviewed by a doctor, regardless of which medication is used.

Weight-loss effectiveness

Clinical studies suggest that tirzepatide may lead to greater average weight loss than liraglutide. However, averages do not tell the full story.

In real-world practice:

• Some patients respond very well to Saxenda

• Others may plateau or experience limited appetite suppression

• Individual metabolism, starting weight, lifestyle factors, and adherence all influence results

  
  

Weight loss is not solely determined by the medication. Nutrition, movement, sleep, stress, and consistency all play important roles.

A GP’s role is to assess whether a medication is delivering meaningful benefit over time and to adjust treatment when needed.

Cost and access considerations

Cost and availability are practical factors that influence treatment choice in New Zealand.

Saxenda has historically been available via private prescription, though supply interruptions have occurred. Patients pay privately, and costs can be significant over time.

Mounjaro, despite international use, is not currently available in New Zealand for weight-loss treatment. This limits its use to future planning rather than immediate prescription.

Because availability can change, it’s important to rely on current medical advice rather than overseas information when making treatment decisions.

Which medication is more suitable?

There is no single “better” option that applies to everyone. Suitability depends on:

• Medical history

• Weight-loss goals

• Side-effect tolerance

• Ability to adhere to dosing schedules

• Availability in New Zealand

• GP clinical judgement

Comparisons like are most useful when discussed with a doctor who understands your individual health profile, rather than viewed as a competition between medications. You can get in touch with a Pocket Lab GP for an online weight loss consultation.

The importance of GP-led decision-making

Prescription weight-loss medications are not cosmetic treatments. They affect appetite hormones, digestion, and metabolism, which is why medical oversight matters.

GP-led care ensures:

• Appropriate patient selection

• Safe dose escalation

• Monitoring for side effects

• Realistic expectations

• Long-term support beyond the prescription

Online GP services like Pocket Lab make this support accessible while maintaining clinical standards and continuity of care.

A note on expectations

It’s important to approach weight-loss medication with realistic expectations. No medication replaces healthy habits, and no treatment works instantly.

The goal is sustainable weight loss that improves health markers, quality of life, and long-term wellbeing — not rapid short-term change.

Final note for NZ patients

While research into newer medications continues, treatment decisions in New Zealand must reflect what is currently safe, available, and appropriate for each patient.

Mounjaro is now available in New Zealand — and you can start your journey with GP-led weight-loss support at Pocket Lab by taking our FREE Eligibility Quiz below.

Check Your Eligibility